Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study.
Aprepitant
CHOP
Complete protection
Complete response
Granisetron
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
08
2019
accepted:
30
10
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
14
12
2019
Statut:
epublish
Résumé
Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for antiemetic therapy has not been established yet. We assessed the efficacy of granisetron plus aprepitant versus granisetron for CHOP or rituximab-CHOP (R-CHOP) regimen-induced nausea and vomiting in malignant lymphoma. This retrospective and observational clinical study included patients who received CHOP or R-CHOP regimen as initiating chemotherapy between July 2010 and March 2016 ( CR rate CP rates did not significantly differ between the groups during the observation period (80.0% versus 83.3%, This study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.
Sections du résumé
BACKGROUND
BACKGROUND
Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for antiemetic therapy has not been established yet. We assessed the efficacy of granisetron plus aprepitant versus granisetron for CHOP or rituximab-CHOP (R-CHOP) regimen-induced nausea and vomiting in malignant lymphoma.
METHODS
METHODS
This retrospective and observational clinical study included patients who received CHOP or R-CHOP regimen as initiating chemotherapy between July 2010 and March 2016 (
RESULTS
RESULTS
CR rate CP rates did not significantly differ between the groups during the observation period (80.0% versus 83.3%,
CONCLUSIONS
CONCLUSIONS
This study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.
Identifiants
pubmed: 31832222
doi: 10.1186/s40780-019-0153-3
pii: 153
pmc: PMC6868793
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24Informations de copyright
© The Author(s). 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Eur J Pharmacol. 2014 Jan 5;722:192-6
pubmed: 24157977
Int J Hematol. 2016 Sep;104(3):378-83
pubmed: 27312042
Curr Probl Cancer. 2017 Nov - Dec;41(6):419-425
pubmed: 29061362
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
J Clin Oncol. 2005 Apr 20;23(12):2822-30
pubmed: 15837996
Int J Hematol. 2016 Dec;104(6):682-691
pubmed: 27612464
J Clin Med Res. 2014 Aug;6(4):252-60
pubmed: 24883150
Support Care Cancer. 1996 Nov;4(6):435-9
pubmed: 8961474
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Int J Clin Oncol. 2015 Oct;20(5):855-65
pubmed: 25681876
In Vivo. 2019 Jul-Aug;33(4):1355-1362
pubmed: 31280230
Leuk Lymphoma. 2017 Apr;58(4):816-821
pubmed: 27545191
Health Qual Life Outcomes. 2003 Sep 17;1:46
pubmed: 14521717